Stefanos Theoharis
Chief Executive Officer OneChain Immunotherapeutics
Stefanos, with more than 20 years of broad experience in the cell and gene therapy space, business development, program management, manufacturing and basic research brings a deep knowledge of the C> sector. Former CBO of Bone Therapeutics, developing specialized cell therapies for orthopaedic disorders. Prior to that he was Senior Vice-President at Cell Medica, CBO at apceth GmbH, and Director, Business Development at Roche, focused on emerging science and technologies. Stefanos also worked at Lazard, the global investment bank, advising on the life science sector on M&A and financing transactions. He holds a PhD from Imperial College London.
Seminars
Tuesday 9th February 2027
Panel Discussion: Progressing Ex Vivo Success into Effective In Vivo Therapies
12:00 pm
- Applying key learnings from ex vivo developments to optimise indication selection, targeting strategies, and clinical translation for in vivo approaches
- Discussing the key scientific, regulatory considerations to streamline the integration of in vivo cell therapies into the pipeline
Wednesday 10th February 2027
Designing Selective Multi-Immune Cell Targeting LVVs with No Off-Target Delivery for In Vivo CAR-Ts Against Solid Tumours
11:15 am
- Engineering immune cell-targeted lentiviral vectors to enable selective in vivo CAR-T engineering while minimising offtarget transduction and associated safety risks
- Targeting multiple immune cell types to combat solid tumours
- Advancing a next-generation in vivo platform to broaden patient access to transformative cell therapies
